Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma

Documenti analoghi

• Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
  di: Syed Naqvi, et al.
  Pubblicazione: (2024-08-01)
• Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies
  di: Jiashun Li, et al.
  Pubblicazione: (2026-05-01)
• Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies
  di: Jiashun Li, et al.
  Pubblicazione: (2026-06-01)
• Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
  di: Juanjuan Zhao, et al.
  Pubblicazione: (2023-08-01)
• Burden of infections and preventive strategies in patients with relapsed/refractory multiple myeloma treated with bispecific antibodies
  di: Sorina-Nicoleta Badelita, et al.
  Pubblicazione: (2026-07-01)